Journal article · 2024 · Open access
Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial
Journal of the American Society of Nephrology, 36(4), 645–656 · Published 25 October 2024 · DOI 10.1681/asn.0000000534
In brief
“Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial” is a 2024 journal article by Richard A. Lafayette and 14 co-authors, published in Journal of the American Society of Nephrology. OpenAlex counts 97 citations as of 22 November 2026, which puts it in the top 3% of works published in 2024 by citations. It is open access under a CC BY licence: the full text is free to read at Journal of the American Society of Nephrology.
- Citations
- 97
- Most cited in
- 2026 (48)
- Field-weighted impact
- 20.53
- References
- 39
- Authors
- 15
Abstract
Key Points This phase 2, double-blind, randomized controlled trial evaluated the complement C5 inhibitor, ravulizumab, in adults with IgA nephropathy. A 30.1% (90% confidence interval, 13.7% to 43.5%) relative reduction in proteinuria for ravulizumab versus placebo was observed at approximately 6 months. Treatment with ravulizumab was well tolerated. Background The complement system plays a central role in the pathogenesis of IgA nephropathy. We present findings from a phase 2 trial of ravulizumab, a complement C5 inhibitor. Methods The Study of Ravulizumab in Proliferative Lupus Nephritis or IgA Nephropathy (NCT04564339) was a randomized, double-blind, placebo-controlled trial of ravulizumab in addition to standard of care. Adults with IgA nephropathy, proteinuria ≥1 g/d, and eGFR ≥30 ml/min per 1.73 m 2 , and on stable renin-angiotensin blockade were randomized 2:1 to ravulizumab (intravenous every 8 weeks) or placebo for 26 weeks. From week 26–50, all participants received open-label ravulizumab. The primary end point was percentage change in proteinuria from baseline to week 26. Secondary end points included change in proteinuria at week 50 and eGFR. Safety, pharmacokinetics, and pharmacodynamics were evaluated. Results Forty-three patients were randomized to ravulizumab and 23 to placebo. At week 26, a statistically significant reduction in proteinuria was observed with ravulizumab versus placebo: −41.9% (95% confidence interval [CI], −50.2% to −32.0%) change in urine protein with ravulizumab and −16.8% (95% CI, −31.8% to 1.6%) change with placebo (30.1% treatment effect; P = 0.005). At week 50, there was a −44.8% (95% CI, −55.1% to −32.1%) change from baseline in urine protein with ravulizumab, and in patients who crossed over from placebo to ravulizumab at week 26, the change from baseline (week 0) to week 50 was −45.1% (−58.0% to −28.4%). The least squares mean change in eGFR from baseline to week 26 with ravulizumab was 0.2 (95% CI, −2.3 to 2.7) ml/min per 1.73 m 2 and with placebo was −4.5 (−7.9 to −1.1) ml/min per 1.73 m 2 . From baseline to week 50, the least squares mean change in eGFR with ravulizumab was −3.9 (95% CI, −6.4 to−1.3) ml/min per 1.73 m 2 , and in patients who crossed over from placebo to ravulizumab at week 26, it was −6.3 (−9.7 to −2.9) ml/min per 1.73 m 2 . Ravulizumab was well tolerated, with an adverse event profile similar to that for placebo. Conclusions An early, sustained, and clinically meaningful reduction in proteinuria and trend toward stabilization of eGFR were observed with ravulizumab versus placebo. A phase 3 trial (NCT06291376) is enrolling. Clinical Trial registry name and…
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Lafayette, R. A., Tumlin, J. A., Fenoglio, R., Kaufeld, J. K., Valdivia, M. Á. P., Wu, M.-S., Huang, S. S., Alamartine, É., Kim, S. G., Yee, M., Kateifides, A. K., Rice, K. C., Garlo, K. G., Barratt, J., & the SANCTUARY Study Investigators. (2024). Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial. Journal of the American Society of Nephrology, 36(4), 645–656. https://doi.org/10.1681/asn.0000000534
MLA 9
Lafayette, Richard A., et al. “Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial.” Journal of the American Society of Nephrology, vol. 36, no. 4, 2024, pp. 645–656. https://doi.org/10.1681/asn.0000000534.
Chicago
Lafayette, Richard A., James Alan Tumlin, Roberta Fenoglio, Jessica Katharina Kaufeld, Miguel Ángel Pérez Valdivia, Mai-Szu Wu, Shih‐Han Susan Huang, et al. 2024. “Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial.” Journal of the American Society of Nephrology 36 (4): 645–656. https://doi.org/10.1681/asn.0000000534.
Harvard
Lafayette, R. A. et al. (2024) ‘Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial’, Journal of the American Society of Nephrology, 36(4), pp. 645–656. doi:10.1681/asn.0000000534.
IEEE
R. A. Lafayette et al., “Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial,” Journal of the American Society of Nephrology, vol. 36, no. 4, pp. 645–656, 2024, doi: 10.1681/asn.0000000534.
BibTeX
@article{lafayette2024efficacy,
title = {{Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial}},
author = {Lafayette, Richard A. and Tumlin, James Alan and Fenoglio, Roberta and Kaufeld, Jessica Katharina and Valdivia, Miguel Ángel Pérez and Wu, Mai-Szu and Huang, Shih‐Han Susan and Alamartine, Éric and Kim, Sung Gyun and Yee, Min and Kateifides, Andreas K. and Rice, Kara Creamer and Garlo, Katherine G. and Barratt, Jonathan and the SANCTUARY Study Investigators},
journal = {Journal of the American Society of Nephrology},
year = {2024},
volume = {36},
number = {4},
pages = {645--656},
doi = {10.1681/asn.0000000534},
url = {https://doi.org/10.1681/asn.0000000534}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2024 | 5 | |
| 2025 | 44 | |
| 2026 | 48 |
Its field-weighted citation impact is 20.53: it has been cited 20.53 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- ravulizumab
- IgA nephropathy
- complement C5 inhibitor
- proteinuria
- complement system
- EGFR
- drug safety
- pharmacokinetics
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Lafayette, R. A., Tumlin, J. A., Fenoglio, R., Kaufeld, J. K., Valdivia, M. Á. P., Wu, M.-S., Huang, S. S., Alamartine, É., Kim, S. G., Yee, M., Kateifides, A. K., Rice, K. C., Garlo, K. G., Barratt, J., & the SANCTUARY Study Investigators. (2024). Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial. Journal of the American Society of Nephrology, 36(4), 645–656. https://doi.org/10.1681/asn.0000000534
How many times has this paper been cited?
97 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Journal of the American Society of Nephrology: sign in and open the full text from this page.
Who wrote this paper?
Richard A. Lafayette, James Alan Tumlin, Roberta Fenoglio, Jessica Katharina Kaufeld, Miguel Ángel Pérez Valdivia, Mai-Szu Wu, Shih‐Han Susan Huang, Éric Alamartine, Sung Gyun Kim, Min Yee, Andreas K. Kateifides, Kara Creamer Rice and 3 more.
What is the DOI of this paper?
10.1681/asn.0000000534, permanently at https://doi.org/10.1681/asn.0000000534. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.